VCP and inclusion body myositis: We have also shown that amplification of the HSR by treatment with arimoclomol ameliorates skeletal muscle pathology in models of IBM, including in mice expressing humanised VCP with the dominant mutation A232E (mVCP), which manifest the characteristic pathological features of IBM [32, 33].